传出细胞增多
急性呼吸窘迫综合征
医学
中性粒细胞胞外陷阱
炎症
HMGB1
支气管肺泡灌洗
安普克
免疫学
肺
内科学
巨噬细胞
化学
蛋白激酶A
生物
细胞生物学
激酶
体外
生物化学
作者
Murielle Grégoire,Fabrice Uhel,Mathieu Lesouhaitier,Arnaud Gacouin,Marion Guirriec,Frédéric Mourcin,Erwan Dumontet,Arnaud Chalin,Michel Samson,Laureline Berthelot,Adrien Tissot,Mallorie Kerjouan,S. Jouneau,Yves Le Tulzo,Karin Tarte,Jaroslaw W. Zmijewski,Jean‐Marc Tadié
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2018-06-25
卷期号:52 (2): 1702590-1702590
被引量:160
标识
DOI:10.1183/13993003.02590-2017
摘要
Exaggerated release of neutrophil extracellular traps (NETs) along with decreased NET clearance and inability to remove apoptotic cells (efferocytosis) may contribute to sustained inflammation in acute respiratory distress syndrome (ARDS). Recent studies in experimental models of ARDS have revealed the crosstalk between AMP-activated protein kinase (AMPK) and high-mobility group box 1 (HMGB1), which may contribute to effectiveness of efferocytosis, thereby reducing inflammation and ARDS severity. We investigated neutrophil and NET clearance by macrophages from control and ARDS patients and examined how bronchoalveolar lavage (BAL) fluid from control and ARDS patients could affect NET formation and efferocytosis. Metformin (an AMPK activator) and neutralising antibody against HMGB1 were applied to improve efferocytosis and NET clearance. Neutrophils from ARDS patients showed significantly reduced apoptosis. Conversely, NET formation was significantly enhanced in ARDS patients. Exposure of neutrophils to ARDS BAL fluid promoted NET production, while control BAL fluid had no effect. Macrophage engulfment of NETs and apoptotic neutrophils was diminished in ARDS patients. Notably, activation of AMPK in macrophages or neutralisation of HMGB1 in BAL fluid improved efferocytosis and NET clearance. In conclusion, restoration of AMPK activity with metformin or specific neutralisation of HMGB1 in BAL fluid represent promising therapeutic strategies to decrease sustained lung inflammation during ARDS.
科研通智能强力驱动
Strongly Powered by AbleSci AI